Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimal antithrombotic strategy for atherosclerotic cardiovascular disease (OACART)
KCT0008458Phase 4Recruiting
- Sponsor
- Seoul National University Bundang Hospital
- Start
- Nov 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of clopidogrel, aspirin, rivaroxaban in coronary arteriosclerosis, arteriosclerosis obliterans, atherosclerotic disease, sponsored by Seoul National University Bundang Hospital. Started Nov 2023; status: recruiting.
02
Drugs
clopidogrelaspirinrivaroxaban
03
Conditions
coronary arteriosclerosisarteriosclerosis obliteransatherosclerotic disease
Beyond the preview
Go deeper on KCT0008458.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0008458.